Latest news newssearch boxGO All Ad hoc Other 06 Feb 2023 Idorsia announces the results of REACT a Phase 3 study of clazosentan in patients following aneurysmal subarachnoid hemorrhage 31 Jan 2023 Idorsia submits European marketing authorisation application for aprocitentan for the treatment of patients with resistant hypertension 09 Jan 2023 Idorsia presents at the 41st J.P. Morgan Healthcare Conference – Achievements in 2022 provide the foundation for our success in 2023 20 Dec 2022 Idorsia submits a New Drug Application to the US FDA for aprocitentan for the treatment of patients with difficult-to-control hypertension 15 Dec 2022 Idorsia initiates OPUS a Phase 3 program to investigate cenerimod for the treatment of patients with systemic lupus erythematosus 12 Dec 2022 Long-term safety and tolerability results with daridorexant in patients with insomnia disorder published in CNS Drugs 05 Dec 2022 Swissmedic approves QUVIVIQ (daridorexant) – a first-in-class treatment for chronic insomnia disorder to improve both nighttime symptoms and daytime functioning 16 Nov 2022 Idorsia and Simcere enter into a licensing agreement for daridorexant in China 15 Nov 2022 QUVIVIQ (daridorexant) – Europe’s first dual orexin receptor antagonist – is now available for patients with chronic insomnia disorder in Italy and Germany 13 Nov 2022 Idorsia congratulates its Chief Scientific Officer Martine Clozel who has been honored by Initiative Switzerland with the Annual Prix Suisse Award 07 Nov 2022 The Lancet and AHA late-breaking science session reports significant and sustained effect of aprocitentan on lowering blood pressure for patients with resistant hypertension 25 Oct 2022 Idorsia announces financial results for the first nine months of 2022 – QUVIVIQ becoming a global brand 03 Oct 2022 Idorsia Japan announces positive results with daridorexant in a Phase 3 study of Japanese patients with insomnia 27 Sep 2022 Idorsia secures additional cash by entering into a building sale and leaseback agreement 26 Jul 2022 Idorsia announces financial results for the first half 2022 – reaching commercial stage 23 May 2022 Positive Phase 3 study with aprocitentan demonstrates significant antihypertensive efficacy in patients with resistant hypertension 10 May 2022 Phase 2a study results in binge eating disorder 03 May 2022 Europe’s first dual orexin receptor antagonist – QUVIVIQ (daridorexant) – granted approval to improve both nighttime symptoms and daytime functioning in adults with chronic insomnia disorder 02 May 2022 Idorsia’s new treatment QUVIVIQ (daridorexant) is now available in the US for adults living with insomnia 26 Apr 2022 Idorsia announces financial results for the first quarter 2022 – first product launched, second in the starting blocks 1 2 3 4 5 6 7 8